311 related articles for article (PubMed ID: 15069715)
21. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
[TBL] [Abstract][Full Text] [Related]
22. [Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma].
Yang B; Lu XC; Zhu HL; Han WD; Wang Y; Fan H; Li SX; Liu Y; Dai HR; Yao SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1244-9. PubMed ID: 21129269
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model.
Lee DH; Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho E; Lee JH; Yu SJ; Kim YJ; Yoon JH
Cancer Biol Ther; 2017 Jan; 18(1):67-75. PubMed ID: 28055304
[TBL] [Abstract][Full Text] [Related]
24. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
[TBL] [Abstract][Full Text] [Related]
25. Effect of RFA and TACE combined with postoperative cytokine-induced killer cell immunotherapy in primary hepatocellular carcinoma.
Ji Q; Fu Y; Zhu X; Wang L; Ling C
J BUON; 2021; 26(1):235-242. PubMed ID: 33721457
[TBL] [Abstract][Full Text] [Related]
26. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
27. Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma.
Zhou P; Liang P; Dong B; Yu X; Han Z; Xu Y
Cancer Biol Ther; 2011 Mar; 11(5):450-6. PubMed ID: 21258206
[TBL] [Abstract][Full Text] [Related]
28. Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice.
Jung NC; Lee JH; Choi HJ; Hwang SU; Song JY; Seo HG; Choi J; Jung SY; Han SG; Lim DS
Immunol Invest; 2016 Aug; 45(6):553-65. PubMed ID: 27410037
[TBL] [Abstract][Full Text] [Related]
29. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.
Yang B; Lu XC; Yu RL; Chi XH; Liu Y; Wang Y; Dai HR; Zhu HL; Cai LL; Han WD
Hematol Oncol; 2012 Sep; 30(3):115-22. PubMed ID: 22972689
[TBL] [Abstract][Full Text] [Related]
30. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma.
Kornacker M; Moldenhauer G; Herbst M; Weilguni E; Tita-Nwa F; Harter C; Hensel M; Ho AD
Int J Cancer; 2006 Sep; 119(6):1377-82. PubMed ID: 16642465
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol.
Rutella S; Iudicone P; Bonanno G; Fioravanti D; Procoli A; Lavorino C; Foddai ML; Lorusso D; Martinelli E; Vacca M; Ipsevich F; Nuti M; Scambia G; Pierelli L
Cytotherapy; 2012 Aug; 14(7):841-50. PubMed ID: 22563888
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of Several Optimization Schemes for the Induction and Expansion of Antibody-Mediated High Efficiency CIK (AMHE-CIK) In Vitro].
Yin X; Xu X; Zhao Y; Wang ZJ; Wang HY; Hu ZB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):191-6. PubMed ID: 26913419
[TBL] [Abstract][Full Text] [Related]
33. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma.
Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R; Guo T
Cancer Biother Radiopharm; 2010 Aug; 25(4):465-70. PubMed ID: 20701541
[TBL] [Abstract][Full Text] [Related]
35. Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.
Bonanno G; Iudicone P; Mariotti A; Procoli A; Pandolfi A; Fioravanti D; Corallo M; Perillo A; Scambia G; Pierelli L; Rutella S
J Transl Med; 2010 Dec; 8():129. PubMed ID: 21138560
[TBL] [Abstract][Full Text] [Related]
36. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
[TBL] [Abstract][Full Text] [Related]
37. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
38. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy.
Zhao X; Ji CY; Liu GQ; Ma DX; Ding HF; Xu M; Xing J
Int J Clin Exp Pathol; 2015; 8(10):13146-55. PubMed ID: 26722513
[TBL] [Abstract][Full Text] [Related]
40. Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.
Doskali M; Tanaka Y; Ohira M; Ishiyama K; Tashiro H; Chayama K; Ohdan H
J Immunother; 2011 Mar; 34(2):129-38. PubMed ID: 21304407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
